{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-25-000013","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.173045+00:00","generated_at":"2026-05-24T02:19:45.491285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Connect Biopharma reports FY2024 net loss $15.6M; cash $93.7M into 2027","bullets":["Revenue $26.0M from Simcere license; no revenue in FY2023.","R&D expense $29.3M (-$23.7M YoY) as Phase 2b asthma/atopic dermatitis trials completed.","Net loss $15.6M ($0.28 EPS) vs $62.1M ($1.13) in FY2023.","Phase 2 trials of rademikibart for acute asthma/COPD start Q2 2025; data expected H2 2026.","CEO Barry Quart leads U.S.-centric shift; HQ relocated to San Diego, transition to domestic filer."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-25-000013","json":"https://secwatch.observer/filing/0001835268-25-000013.json","markdown":"https://secwatch.observer/filing/0001835268-25-000013.md","text":"https://secwatch.observer/filing/0001835268-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000013/0001835268-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526825000013/cntb-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:19:45.491285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}